Raptor Pharmaceutical Corp Form 8-K March 15, 2013 **UNITED STATES** SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K **CURRENT REPORT** Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2013 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Delaware 000-25571 86-0883978 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 9 Commercial Blvd., Suite 200, Novato, California 94949 (Address of principal executive offices and Zip Code) Registrant's telephone number, including area code: (415) 382-8111 (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition.

On March 14, 2013, Raptor Pharmaceutical Corp., a Delaware corporation (the "Company"), issued a press release reporting its financial results for the Company's four month transition period from September 1, 2012 to December 31, 2012. A copy of the press release is being furnished as Exhibit 99.1 and is incorporated herein by reference. The information included in this Item 2.02 of this Current Report on Form 8-K, including the information incorporated by reference in the exhibit hereto, shall not be deemed "filed" for purposes of, nor shall it be deemed incorporated by reference in, any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(4) E-1-11-14-

| (d) | Exhibits. | | |
|--------|--|-----------|--------------------------------------|
| | | Furnished | İ |
| Exhibi | t | Here | Incorporated by Reference |
| No. | Exhibit Description | with | Form File No. Exhibit Filing Date By |
| 99.1 | Press release issued by the Company dated as of March 14, 2013 | X | · |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

RAPTOR PHARMACEUTICAL CORP.

Date: March 14, 2013 By:

y: /s/ Kim R. Tsuchimoto

Name: Kim R. Tsuchimoto Title: Vice President, Finance

Exhibit Index

Exhibit Furnished
Exhibit Here Incorporated by Reference

No. Exhibit Description with Form File No. Exhibit Filing Date Filed
By

99.1 Press release issued by the Company dated as of March 14, 2013